OKYO Pharma Ltd
Business
OKYO Pharma Ltd is a clinical-stage biopharmaceutical company developing next-generation therapeutics for inflammatory eye diseases and ocular pain. Its main product candidates include urcosimod, a lipidated peptide that targets the ChemR23 GPCR to reduce ocular inflammation and neuropathic corneal pain, and exploratory lipidated BAM analogues such as OK-201. The company’s activities center on research and clinical development programs, intellectual property licensing and collaborative clinical research partnerships. OKYO conducts trials and engages with regulators and collaborators across the United States, Europe and other international markets through clinical sites, license arrangements and partner networks.
Summary from filing dated 2025-07-18
Financials
Latest annual snapshot (FY2025, period end 2025-03-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-4.70M |
| Total assets | $3.68M |
| Total liabilities | $9.23M |
| Stockholders' equity | — |
| Operating cash flow | — |